Skip to main content
Premium Trial:

Request an Annual Quote

CTCA Combines Allscripts, NantHealth Offerings Into New Treatment Platform

NEW YORK (GenomeWeb) – Cancer Treatment Centers of America said today that it is collaborating with NantHealth and Allscripts to provide a new clinical decision support service called Clinical Pathways.

The platform merges NantHealth's Eviti clinical decision support tool and Allscripts' Sunrise electronic health record system to allow doctors to investigate potential treatments and order them through a single system. Physicians input data on patients' clinical status, as well as any molecular or genomic biomarkers, and the Eviti system provides a collation of the latest available research, recommended treatment regimens, and health economic information from the company's unbiased evidence-based medical library.

According to NantHealth, this database includes over 2,700 treatment regimens covering all cancers and cancer subtypes. Doctors can then order their therapy of choice at the point of care through the Allscripts Sunrise EHR.

NantHealth and Allscripts first announced their collaboration to develop precision medicine solutions in 2015. Soon after, Allscripts announced it had acquired a 10 percent stake in NantHealth for $200 million in cash

"Cancer Treatment Centers of America, Allscripts, and NantHealth began planning this project in early 2016 to help patients and providers alike benefit from the clinical capabilities of an integrated solution," Allscripts CEO Paul Black said in a statement. "Through a careful analysis of clinical workflows and strategic design sessions, we've delivered a solution that enhances and improves the chemotherapy regimen selection and ordering process, and ultimately, the quality of care CTCA provides to its patients."

CTCA said the new tool is available for patients at all five of its hospital locations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.